{ "items": [ "\n\n
\n \n 6 March 2019\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nLorenz Von Seidlein tells SciDev.Net that mass drug administration as \u201cpresumptive treatment\u201d to clear the parasite reservoir was carried out in eight villages spread across Cambodia, Lao PDR, Myanmar and Vietnam. By the third month, the prevalence of P. falciparum had decreased by 92 % in those villages. Over the subsequent nine months, P. falciparum infections returned but stayed well below baseline levels, showing that MDA can stop transmission of falciparum malaria and reduce its prevalence in SE Asia, where resistance to artemisinin has hampered elimination efforts.
\n \n\n\n \n 26 February 2019\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nOn 12 Feb 2019, Professor Arjen Dondorp published a new book: Sepsis Management in Resource-limited Settings. The result of a 3-year project led by MORU and the European Society of Intensive Care Medicine (ESICM), the book was written by critical care physicians from around the globe.
\n \n\n\n \n 12 February 2019\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nOn 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing antimalarial drugs.
\n \n\n\n \n 18 January 2019\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nA recent WWARN individual patient meta-analysis has gathered 18 published and unpublished studies from Africa and Asia to explore the relationships between identified Kelch 13 mutant alleles and delayed parasite clearance. The study results show one P. falciparum specific mutant and 20 pfk13 propeller region mutant alleles are strongly associated with the slow clearance phenotype, including 15 mutations that have not been confirmed before. It was reassuring that no pfk13 alleles associated with slow parasite clearance were observed in the parasites from African studies gathered between 2000-2017.
\n \n\n\n \n 16 January 2019\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nDoctors in Northern Cambodia are trialling a new drug combination therapy in a bid to stop the spread of drug resistant strains of malaria.
\n \n\n\n \n 18 December 2018\n \n
\n\n \n\n \n\n \n \n \n \n General\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nAn inspiring doctor and scientist of great compassion and intellect, Sir David Weatherall died 8 Dec 2018. A Nuffield Professor of Medicine, founder of the MRC Weatherall Institute of Molecular Medicine and a member of Wellcome\u2019s Board throughout the 1990s, Sir David was instrumental in the creation of MORU back in 1979.
\n \n\n\n \n 18 December 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nA new Piperaquine Pharmacokinetics in Pregnancy Study Group is now open for participation at WWARN. The analysis hopes to determine the effect of pregnancy on the pharmacokinetic (PK) properties of piperaquine and contribute evidence to inform decisions on the use and optimal dosing of piperaquine in pregnant women.
\n \n\n\n \n 12 December 2018\n \n
\n\n \n\n \n\n \n \n \n \n General\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nThis article, written by Professor Nick Day at MORU and published in the November 2018 issue of the Oxford Alumni Newsletter, describes in a nutshell all the good work our Centre is doing to promote Global Oxford.
\n \n\n\n \n 20 November 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nProgress against malaria has stalled, and the disease remains a significant threat to billions of people despite the expensive, decades-long efforts to contain it. In an encouraging development, MORU reported complete success in curing hundreds of patients in Southeast Asia with new three-drug combinations mixing fast-acting artemisinin with two longer-lasting drugs. It it hoped that triple therapy should become the standard for malaria treatment.
\n \n\n\n \n 16 November 2018\n \n
\n\n \n\n \n\n \n \n \n \n Conferences & meetings\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nVisit the Radcliffe Science Library before 4th January 2019 to see a new art exhibition of 14 prints illustrating the global health impact of poor quality medicines. The proliferation of poor quality medicines is an important but neglected public health problem, threatening millions of people all over the world, both in developing and wealthy countries.
\n \n\n\n \n 9 November 2018\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n General\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford University has been ranked as the world's best institution for medical and health teaching and research in the Times Higher Education World University Rankings for the eighth consecutive year. This ranking is based on criteria measuring teaching, research, industry income, international outlook and citations. It was noted that both research and clinical trials are supported by our network of international research units in Africa and Asia.
\n \n\n\n \n 9 November 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nA systematic review analyses the results of 177 trials conducted between 1982 and 2016, including 18,436 patients who underwent electrocardiographic evaluation during malaria clinical trials. Nick White and colleagues found that serious cardiovascular side effects, which include sudden cardiac death, are very rare in the treatment of malaria with quinoline antimalarials. The work emphasises the importance of continued pharmacovigilance with the increasing use of quinoline antimalarials in mass treatment strategies such as intermittent preventative treatment and mass drug administration.
\n \n\n\n \n 27 October 2018\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nCTMGH have been nominated for the Market Research Society President's Medal, awarded annually to an organisation that conduct extraordinary research but who might not be recognised through the usual channels. Our Centre is noted for its ingenious use of freely available online satellite images to gath data on the use of antibiotics in unmapped and inaccessible villages in rural Thailand and Laos. Researchers use the images to identify representative clusters of potential participants.
\n \n\n\n \n 24 October 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nCome and meet us at the ASTMH conference, to enjoy science over a pint and bite to eat: Outbreaks, from Ebola to Zika on Mon 29th Oct. Mosquitoes, the most dangerous animals in the world on Tue 30th. Global health terror night: bats, mites and other creepy crawlies on Wed 31st. We will be at The Vintage, 3121 Magazine St, New Orleans, 7-9pm
\n \n\n\n \n 4 October 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nOn 4 Oct 2018, the MORU Malaria Dept, in collaboration with the Global Sepsis Alliance (GSA), hosted the inaugural meeting of a proposed Asian Sepsis Alliance in Bangkok.
\n \n\n\n \n 28 September 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nIn this Science blog, field researchers, Dr Giacomo Zanello, Dr Marco Haenssgen, Ms Nutcha Charoenboon and Mr Jeffrey Lienert explain the importance of continuing to improve survey research techniques when working in rural areas of developing countries.
\n \n\n\n \n 12 September 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nMORU is participating in a project to reduce antibiotic resistance on farms in Asia by educating farmers. In his first 12 years working as a vet in Bangladesh, Bikash Chandra Saha routinely prescribed antibiotics. Then he learned of the devastating impact of antimicrobial resistance on human health - and it revolutionized his treatment choices.
\n \n\n\n \n 4 September 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nA team of researchers led by Yoel Lubell at MORU and IDDO used data from the USA and Thailand to link the consumption of antibiotics with the direct and indirect costs of treating patients for five drug-resistant bacterial infections.
\n \n\n\n \n 22 August 2018\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford's Medical Sciences Divisional Panel has conferred the title of Associate Professor on three members of our academic staff: Rogier van Doorn (OUCRU), Lorenz von Seidlein (MORU) and George Warimwe (KWTRP). This title is awarded in recognition of their distinction in their respective fields and contributions to the research and teaching, and we congratulate them on their success.
\n \n\n\n \n 26 July 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nScientists are racing to stamp out the disease in Southeast Asia before unstoppable strains spread. This article features MORU, SMRU and colleagues, and explains what is happening and what we are doing to eliminate drug-resistant malaria in Southeast Asia before it spreads
\n \n\n\n \n 13 June 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nCurrent recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Professor Joel Tarning.
\n \n\n\n \n 8 June 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nOne of the world\u2019s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who\u2019d taken the drug dihydroartemisinin-piperaquine (DHA-PPQ). There is such a low risk of sudden unexpected death from DHA-PPQ, one of the world\u2019s most effective medicines to treat malaria, that there is no need to limit its current use.
\n \n\n\n \n 25 May 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nPrimaquine can be used to prevent the transmission of falciparum malaria from human to mosquito. Bob Taylor and colleagues at the Mahidol Oxford Research Unit (MORU) have developed an age-based regimen for single low-dose primaquine to block the transmission of malaria in sub-Saharan Africa.
\n \n\n\n \n 11 May 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nDr Marco J Haenssgen discusses the application of management thinking to solving the growing global problem of antimicrobial resistance.
\n \n\n\n \n 25 April 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe rapid elimination of potentially untreatable P. falciparum malaria in South-East Asia is possible, according to a ground-breaking new study published today in The Lancet. The study authors say that setting up community-based malaria clinics for early diagnosis, treatment and monitoring, combined with mass antimalarial drug administration (MDA) to everyone living in \u2018hotspot\u2019 areas.
\n \n\n\n \n 20 April 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nITV News has travelled across the world to report on the growing global threat of the spread of deadly drug-resistant 'super bugs'. In the first of their three-part series, they investigate the frontline fight against deadly malaria parasites in South East Asia threatening a new global emergency.
\n \n\n\n \n 20 April 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \n18 April 2018 (London) \u2013 The United Kingdom\u2019s Department for International Development (DFID) announced that it will commit \u00a39.2 million (USD 13.15 million) of research funding to DeTACT (Development of Triple Artemisinin Combination Therapies), a large multi-centre trial in 5 Asian and 10 African countries that aims to develop two new safe and effective malaria treatments using combinations of existing antimalarial drugs.
\n \n\n\n \n 17 April 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nAs the second largest international donor, the UK has been at the forefront of efforts to reduce the number of cases for many years by investing in treatment, prevention and research, including the fight against the threat of drug resistance. The UK has announced further support for the fight against malaria to save more than 120,000 lives ahead of a Malaria Summit tomorrow with Commonwealth leaders.
\n \n\n\n \n 10 April 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nPailin, a small settlement nestling in tropical rainforest near Cambodia\u2019s border with Thailand, lies at the heart of a region that has seen successive waves of resistance to malaria drugs arise in local people and then spread across the globe. As new waves of the disease threaten our health, worried scientists want to conduct a mass inoculation in a Cambodian region where new vaccines always seem to stop being effective.
\n \n\n\n \n 10 April 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nGiving paracetamol (acetaminophen) to patients ill with severe malaria made them less likely to develop potentially fatal kidney failure. Each year severe malaria causes close to half a million deaths globally. Acute kidney injury occurs in 40% of adults and at least 10% of children with severe malaria, killing an estimated 40% of these adults and 12-24% of the children. The study reported for the first time that giving regular doses of paracetamol protects the kidney in adult patients with severe falciparum malaria.
\n \n\n\n \n 16 March 2018\n \n
\n\n \n\n \n\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nFIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.
\n \n\n\n \n 9 March 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nIn collaboration with Cambodian authorities, MORU are running the Village Drama Against Malaria project for the third year. The project, which runs in 10 remote villages in March 2018, aims to create awareness about malaria prevention and early treatment.
\n \n\n\n \n 23 February 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nMelioidosis is a bacterial infection that quietly causes thousands of deaths each year. Meet Direk Limmathurotsakul, the doctor who made it his mission to make the world take notice.
\n \n\n\n \n 31 January 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nTo fight the growing global threat of antibiotic-resistant bacteria, food labels around the world should include an \u2018antibiotic footprint\u2019 section that clearly shows the type and amount of antibiotics used to produce that food, say scientists in a study led by Associate Professor Direk Limmathurotsakul.
\n \n\n\n \n 9 January 2018\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nInterested in science? Looking for a fun night out? Want to know what Pint of Science is all about? Come and join us for a one-night-only special, Casa Azul in Bangkok on the 1st February, where three world-class researchers will delve deep into the world of science.
\n \n\n\n \n 5 December 2017\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nWellcome is announcing new collaborations with six institutions to find new ways to translate scientific discoveries into real world impact. The partnership with MORU will focus on closing the gap between research and implementing interventions, building capacity and expertise to support early translation to improve the health of people in low-income countries.
\n \n\n\n \n 22 November 2017\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Arjen Dondorp and colleagues are inching their way across the fringes of five Southeast Asian countries to test a triple combination therapy of antimalarial drugs. Results from the trial, being conducted in rural corners of Cambodia, Laos, Myanmar, Thailand and Vietnam, are due by mid-2018. This trial is also mentioned in the New York Times.
\n \n\n\n \n 2 November 2017\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nA collaboration between the University of Oxford and Thailand\u2019s Mahidol University has been shortlisted for the prestigious 2017 Newton Prize for its project aiming to understand the early stages of scrub typhus in Thailand.
\n \n\n\n \n 17 October 2017\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nCongratulations to Professor Sir Nick White, elected to the National Academy of Medicine (US). Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
\n \n\n\n \n 10 October 2017\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nThe world\u2019s number-one treatment for malaria is on the brink of failure because of a new strain of drug-resistant parasites\u200a\u2014\u200aunless health policymakers take action. Professor Sir Nicholas White says that the mosquito-borne parasite responsible for severe malaria is now showing resistance to the prime treatment, Artemisinin Combination Therapy (ACT), across South-East Asia. If this resistance jumps to Africa, he warns, the tragedy will be on a massive scale.
\n \n\n